CSPC Pharmaceutical Group (HKG:1093) agreed to sell its 30.07% interest in the non-core business Beijing Guoxin Huijin for 230 million yuan, according to a Hong Kong bourse filing Thursday.
Shares of the firm gained nearly 4% in afternoon trade Friday.
The firm will cease to hold any interest in Beijing Guoxin Huijin, a media communication platform operator, following the disposal.
CSPC Pharmaceutical said it expects to record a 15 million yuan loss from the sale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.